Is gene therapy soon going to be used clinically in advanced cancer of the prostate?

[1]  J. Simons.  Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. , 1997, Hinyokika kiyo. Acta urologica Japonica.

[2]  R. Barth,et al.  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Moul,et al.  Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector , 1997, International journal of cancer.

[4]  W. Fair,et al.  Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. , 1997, The Urologic clinics of North America.

[5]  A. Belldegrun,et al.  Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. , 1997, Cancer research.

[6]  T. Thompson,et al.  Adenovirus‐mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer , 1997, International journal of cancer.

[7]  D. Johnston,et al.  Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. , 1996, Human gene therapy.

[8]  J. Eastham,et al.  Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. , 1996, Human gene therapy.

[9]  A. Passaniti,et al.  Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. , 1995, Cancer research.

[10]  E. Marshall.  Gene therapy's growing pains , 1995, Science.

[11]  E. Gelmann,et al.  Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. , 1995, Cancer research.

[12]  E. Gilboa,et al.  Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. , 1994, Cancer research.

[13]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[14]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[15]  J. Gschwend.  Apoptose – Grundlagen und Bedeutung des programmierten Zelltods für das Prostatakarzinom , 1996, Der Urologe A.